公开(公告)号：US20240358711A1

公开(公告)日：2024-10-31

申请号：US18292918

申请日：2022-07-28

申请人： IMMUNYX PHARMA LTD. ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ,  Hadasit Medical Research Services and Development Ltd.

发明人： Seth Jonah SALPETER ,  Meital NAIM ,  Zvika GRANOT ,  Zvi Gregorio FRIDLENDER

IPC分类号： A61K31/55 ,  A61K31/137 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/64 ,  A61P29/00

CPC分类号： A61K31/55 ,  A61K31/137 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/64 ,  A61P29/00

摘要： Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.

公开(公告)号：US20240358634A1

公开(公告)日：2024-10-31

申请号：US18603065

申请日：2024-03-12

申请人： DOMPE FARMACEUTICI S.P.A ,  The Regents of the University of California

发明人： Jay LICHTER ,  Andrew M. TRAMMEL ,  Fabrice PIU ,  Qiang YE ,  Michael Christopher SCAIFE ,  Benedikt VOLLRATH ,  Sergio G. DURON ,  Luis A. DELLAMARY ,  Carl LEBEL ,  Jeffrey P. HARRIS

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/05 ,  A61K31/13 ,  A61K31/137 ,  A61K31/325 ,  A61K31/43 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5517 ,  A61K38/18 ,  A61K39/00 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  C07K16/24

CPC分类号： A61K9/0046 ,  A61K9/06 ,  A61K9/127 ,  A61K9/14 ,  A61K9/16 ,  A61K31/05 ,  A61K31/13 ,  A61K31/137 ,  A61K31/325 ,  A61K31/43 ,  A61K31/436 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/5517 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1825 ,  A61K38/185 ,  A61K38/1858 ,  A61K38/1883 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  C07K16/241 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76

摘要： Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or Auris interna target areas, or via perfusion into the auris media and/or Auris interna structures.

公开(公告)号：US20240342400A1

公开(公告)日：2024-10-17

申请号：US18626527

申请日：2024-04-04

申请人： Flik Therapeutics, Inc.

发明人： Brendan Heiden

IPC分类号： A61M11/04 ,  A61K31/137 ,  A61K31/465 ,  A61K31/498 ,  A61M15/06 ,  G16H20/10

CPC分类号： A61M11/042 ,  A61K31/137 ,  A61K31/465 ,  A61K31/498 ,  A61M11/047 ,  A61M15/06 ,  G16H20/10

摘要： A smoking cessation system may include a nicotine delivery device to deliver a mixture in an aerosol form to a user, through pulmonary delivery. The mixture may include nicotine. The system may be prescription, over-the-counter, or non-prescription based. The smoking cessation system may also include a health hub to communicate with the nicotine delivery device and to control operation of the nicotine delivery device based on information. Such information may include, for example, information relating to the use of the nicotine delivery device by the user. One or more additional devices (e.g., a continuous monitoring device that detects nicotine content and use, including through metabolites such as cotinine or carbon monoxide) may communicate one or more items of the information to the health hub for the purpose of assisting the user to quit smoking.

公开(公告)号：US20240342117A1

公开(公告)日：2024-10-17

申请号：US18672318

申请日：2024-05-23

申请人： De Motu Cordis Pty Ltd

发明人： John Fraser ,  Sean Dalziel ,  Teresa Iley ,  Jonathan Brazier ,  Patrick Joseph Lynch ,  John Fredatovich ,  Benjamin Barnaby Trout

IPC分类号： A61K31/137 ,  A61K9/00 ,  A61K47/26

CPC分类号： A61K31/137 ,  A61K9/0075 ,  A61K47/26

摘要： The present disclosure relates to an inhalable formulation, suitable for use in a dry powder inhaler, for the delivery of epinephrine, or a pharmaceutically acceptable salt or derivative thereof. The inhalable formulation further comprises a solid carrier and results in a stable formulation with useful physical properties for delivery to the lungs of a subject in need of epinephrine.

公开(公告)号：US20240335399A1

公开(公告)日：2024-10-10

申请号：US18271188

申请日：2023-04-23

申请人： HQ PHARMA (SHANGHAI) CO., LTD.

发明人： Dunwei He ,  Jiezi Qin ,  Yuzhang Hu

IPC分类号： A61K31/137 ,  A61K9/20 ,  A61K9/46 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

CPC分类号： A61K31/137 ,  A61K9/0007 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2036 ,  A61K9/205 ,  A61K9/2095 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

摘要： Disclosed are a phenylephrine hydrochloride-containing tablet, a preparation method and use. The method for preparing a phenylephrine hydrochloride-containing tablet includes: mixing a granule A with other granules to be uniform to obtain a mixture, and subjecting the mixture to tablet pressing to obtain the phenylephrine hydrochloride-containing tablet; wherein the granule A is prepared by dry granulation, and contains phenylephrine hydrochloride as a single active pharmaceutically ingredient, the other granules comprise at least one selected from the group consisting of a granule B and a granule C, and the granule B contains acetaminophen as an active pharmaceutical ingredient, and the granule C contains dextromethorphan hydrobromide and chlorpheniramine maleate as active pharmaceutical ingredients.

公开(公告)号：US12109178B2

公开(公告)日：2024-10-08

申请号：US17821342

申请日：2022-08-22

申请人： ANTECIP BIOVENTURES II LLC

发明人： Herriot Tabuteau

IPC分类号： A61K31/138 ,  A61K9/00 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

CPC分类号： A61K31/138 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/485 ,  A61P25/24

摘要： Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

公开(公告)号：US20240325543A1

公开(公告)日：2024-10-03

申请号：US18615167

申请日：2024-03-25

申请人： Johnson & Johnson Consumer Inc.

发明人： Charleine Apangha Ngantsan ,  Vincent Chen ,  Julia Coskey ,  Michael Costante

IPC分类号： A61K47/26 ,  A61K9/10 ,  A61K31/09 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/485 ,  A61K31/495 ,  A61K41/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

CPC分类号： A61K47/26 ,  A61K9/10 ,  A61K31/09 ,  A61K31/137 ,  A61K31/138 ,  A61K31/167 ,  A61K31/192 ,  A61K31/445 ,  A61K31/451 ,  A61K31/485 ,  A61K31/495 ,  A61K41/0004 ,  A61K47/10 ,  A61K47/12 ,  A61K47/36 ,  A61K47/46

摘要： Therapeutic liquid compositions useful in the treatment of various conditions comprising a natural bulk sweetener that has a low fructose content.

公开(公告)号：US20240316146A1

公开(公告)日：2024-09-26

申请号：US18260677

申请日：2022-01-07

申请人： Bexion Pharmaceuticals Inc.

发明人： Ray Takigiku ,  Darren P. Wolfe ,  Anne Mary Noonan ,  Robert Wesolowski ,  Charles A. Cruze, III ,  Gilles Hugues Tapolsky ,  Richard Charles Curry, III ,  Michael Gazda

IPC分类号： A61K38/17 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/395 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

CPC分类号： A61K38/1709 ,  A61K9/127 ,  A61K31/135 ,  A61K31/137 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/282 ,  A61K31/335 ,  A61K31/337 ,  A61K31/381 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/69 ,  A61K31/7048 ,  A61K33/243 ,  A61K38/07 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/24 ,  A61P35/00

摘要： Disclosed herein are methods for reducing neuropathy and neuropathic symptoms and/or promoting neurogenesis, neuritogenesis, neuroprotection and neuroregeneration using saposin C-phospholipid compositions. Also disclosed are methods for treating cancer by administering a saposin C-phospholipid nanovesicle formulation and one or more antineoplastic agents or immune checkpoint inhibitors, and kits for the treatment of cancer comprising, in separate containers, (a) a saposin C-phospholipid pharmaceutical composition, and (b) a pharmaceutical composition containing an antineoplastic agent or a pharmaceutical composition containing an immune checkpoint inhibitor.

公开(公告)号：US20240315971A1

公开(公告)日：2024-09-26

申请号：US18592719

申请日：2024-03-01

申请人： Lotus BioPharma Inc.

发明人： Chao Li ,  Nancy L. Li ,  Kingteh Lin

IPC分类号： A61K9/16 ,  A61K31/137 ,  A61K31/18 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4725

CPC分类号： A61K9/1647 ,  A61K9/1694 ,  A61K31/137 ,  A61K31/18 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4725

摘要： This disclosure provides injectable microsphere formulations capable of controlled long-term sustained release. The disclosed microsphere formulations demonstrate a zero-order release of active agents over a predetermined period of time. Also disclosed are methods of preparing the microsphere formulations and methods of use thereof. The disclosed methods can be readily scaled up while maintaining a high drug encapsulation efficiency.

公开(公告)号：US20240315965A1

公开(公告)日：2024-09-26

申请号：US18546085

申请日：2022-02-10

申请人： NATURAL EXTRACTION SYSTEMS, LLC

发明人： Douglas G. METCALF

IPC分类号： A61K9/08 ,  A61K31/055 ,  A61K31/12 ,  A61K31/122 ,  A61K31/137 ,  A61K31/343 ,  A61K31/352 ,  A61K31/355 ,  A61K31/365 ,  A61K31/4741 ,  A61K31/565 ,  A61K47/02 ,  A61K47/10

CPC分类号： A61K9/08 ,  A61K31/055 ,  A61K31/12 ,  A61K31/122 ,  A61K31/137 ,  A61K31/343 ,  A61K31/352 ,  A61K31/355 ,  A61K31/365 ,  A61K31/4741 ,  A61K31/565 ,  A61K47/02 ,  A61K47/10

摘要： This patent document describes excipients that allow certain bioactive agents that exist as hydrophobic molecules to be reformulated as anions that display improved hydrophilicity, which can improve the bioavailability and pharmacokinetics of broad classes of pharmaceuticals.